Litigation involving US Patent 6281230

6281230

Cases

Active

2 closed

Filed

2010–2012

Top venue

D. New Jersey

1 case

Celgene Corporation v. Natco Pharma Limited et al.

settled; consent judgment entered

Docket:: 2:10-cv-05197 (SDW)(LDW); consolidated with 2:12-cv-04571 (SDW)(LDW)
Court:: U.S. District Court, District of New Jersey (Newark)
Filed:: 2010-10-08
Terminated:: 2016-01-05

Patents:6555554 5635517 6045501 6315720 6561976 6561977 6755784 7119106 7465800 6281230 8288415

π Celgene Corporation Δ Natco Pharma Limited Δ Arrow International Limited Δ Watson Laboratories, Inc.

Celgene asserted multiple patents, including the '554 patent, against Natco's lenalidomide ANDA No. 201452. The '554 claims were dismissed without prejudice by stipulation on March 26, 2015; the overall case settled with a consent judgment entered January 4, 2016, and terminated January 5, 2016.

Celgene Corp. v. Natco Pharma Ltd.

consolidated

Docket:: 2:12-cv-04571 (SDW)(LDW)
Court:: U.S. District Court, District of New Jersey
Filed:: 2012-07-20

Patents:6555554 5635517 6281230 7189740 7977357

π Celgene Corp.Δ Natco Pharma Ltd.

Related patent-infringement action asserting the '517, '230, '740, '569, '357 and '219 patents; consolidated with the 2010 action by order dated November 9, 2012. The narrative could not confirm that the '554 patent was separately asserted in this 2012 action.